Type 3 Autoimmune Pancreatitis: What Do We Know So Far?

Review OA: gold CC-BY-NC-4.0
📄 Open PDF View on PubMed View at publisher

Abstract

The increasing use of immune checkpoint inhibitors (ICIs) in cancer treatment has led to a rise in immune-related adverse events (irAEs). Type 3 autoimmune pancreatitis (AIP-3) has been proposed as a rare form of pancreatic injury induced by ICIs with autoimmune pancreatitis-like features and variable presentations. Its diagnosis is not straightforward. Moreover, the role of available therapeutic options, particularly mainly glucocorticosteroids (GCS), remains uncertain. Currently, there are no clear guidelines for AIP-3 management. Data on AIP-3 are derived mainly from small retrospective studies and provide limited-quality evidence. In addition, the diagnostic criteria and management of AIP-3 vary substantially between studies. Some researchers have classified asymptomatic pancreatic enzyme elevations during ICI therapy as AIP-3; however, isolated hyperlipasemia should not be considered sufficient for this diagnosis. This comprehensive, narrative review summarizes current knowledge about AIP-3 and discusses epidemiology, etiopathogenesis, clinical presentations, diagnosis, and treatment based on the most recent evidence.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

SciLite annotations

chemicals 17
steroid corticosteroid prednisone prednisolone prednisone prednisolone etanercept prednisolone azathioprine mycophenolate mofetil steroid alcohol pembrolizumab pembrolizumab alcohol gadolinium corticosteroid
organisms 1
men 2004071

Source provenance

europepmc
last seen: 2026-11-15T09:34:25.365398+00:00
scilite
last seen: 2026-11-15T10:16:09.319260+00:00
unpaywall
last seen: 2026-11-16T06:37:28.113292+00:00
License: CC-BY-NC-4.0